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Abstract
Background: Cannabis, in herbal form, is widely used as self-medication by patients with diseases
such as HIV/AIDS and multiple sclerosis suffering from symptoms including pain, muscle spasticity,
stress and insomnia. Valid clinical studies of herbal cannabis require a product which is acceptable
to patients in order to maximize adherence to study protocols.
Methods: We conducted a randomized controlled crossover trial of 4 different herbal cannabis
preparations among 8 experienced and authorized cannabis users with chronic pain. Preparations
were varied with respect to grind size, THC content and humidity. Subjects received each
preparation on a separate day and prepared the drug in their usual way in a dedicated and licensed
clinical facility. They were asked to evaluate the products based on appearance (smell, colour,
humidity, grind size, ease of preparation and overall appearance) and smoking characteristics (burn
rate, hotness, harshness and taste). Five-point Likert scores were assigned to each characteristic.
Scores were compared between preparations using ANOVA.
Results: Seven subjects completed the study, and the product with highest THC content (12%),
highest humidity (14%) and largest grind size (10 mm) was rated highest overall. Significant
differences were noted between preparations on overall appearance and colour (p = 0.003).
Discussion: While the small size of the study precludes broad conclusions, the study shows that
medical cannabis users can appreciate differences in herbal product. A more acceptable cannabis
product may increase recruitment and retention in clinical studies of medical cannabis.
Background
It is now well-recognized that Cannabis sativa (marijuana,
weed, pot) is being used by patients with chronic debili-
tating diseases such as HIV/AIDS [1], chronic non-cancer
pain [2], epilepsy [3], multiple sclerosis [4] and amyo-
trophic lateral sclerosis [5] for the management of symp-
toms such as pain, nausea, poor sleep, anxiety and stress.
Since 2002, cannabis for medical use has been produced
by Prairie Plant Systems Inc (PPS) under license to Health
Canada [6]. Cannabis is cultivated for use in clinical trials,
open-label safety studies [7], and for distribution to per-
sons authorized under the Medical Marihuana Access Reg-
ulations (MMAR) to use marihuana for medical purposes
[8]. A number of authorized persons using this product
initially reported concerns about the product, include the
dryness, grind size (defined as the size of the particles after
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grinding raw herbal material), and tetrahydrocannabinol
(THC) content of the cannabis material [9].
To improve the acceptability of the cannabis product pro-
vided to patients and to facilitate recruitment and reten-
tion of research subjects in clinical trials, Health Canada
and PPS explored mechanisms to vary herbal cannabis
products with varying levels of humidity, THC content,
and grind size. This study was conducted to evaluate sev-
eral herbal cannabis presentations in which dryness, grind
size and THC content were varied. The aims of the study
were to determine experienced users' preference for can-
nabis products, and to determine whether there was any
consistent pattern towards a preferred product.
Methods
A randomized, double-blind study of cannabis products
was undertaken over a six week period in June-July 2004.
Subjects were all current holders of valid authorizations to
possess cannabis under the Medical Marijuana Access Reg-
ulations, and were currently using cannabis for medical
purposes. Subjects agreed not to drive to or from their
scheduled appointments.
Four (4) different PPS preparations of Cannabis sativa were
evaluated; an identical species was used for all prepara-
tions. THC content was varied by blending the flowering
heads with leaves from lower down the plant. The product
was milled using a dry conical mill (Quadro® Comill®,
Waterloo, Ontario), with particle size varied using screens
with circular holes of 5 or 10 mm diameter. Cannabis
preparations were packaged at PPS in 30 gram bags and
labeled as Presentation # 1 to Presentation # 4 prior to
shipment to the site pharmacy. The site pharmacist
weighed 1 g quantities of each preparation (LP 3200D
scale, Sartorius, Canada). The drug was repackaged in
plastic vials closed with a soft plastic/rubber top, which
were then dispensed to the study nurse as needed on the
days of use. The product was weighed and transferred
from the original package to the dispensing container
within 5 minutes, and the ambient temperature and
humidity conditions in the pharmacy were recorded at the
time of preparation (Digital Hygrometer DHM-010, Dav-
idoff, Canada). The original package was resealed imme-
diately after weighing the required amount of product.
The characteristics of the products were determined using
a specially designed questionnaire. Items consisted of 5-
point Likert scales and included physical characteristics
(smell (0: very unpleasant; 4: very pleasant), humidity (0:
unacceptably dry; 4: optimum humidity), appearance (0:
looks very bad; 4: looks excellent), particle size (0: very
poor, 4: excellent), colour (0: very poor, 4: excellent) and
ease of preparation (0: very hard to use; 4: very easy to
use) and smoking characteristics (hotness (0: very hot; 4:
very cool), harshness (0: very harsh; 4: very smooth), burn
rate (0: burns too fast; 4: burns just right), and taste (0:
worse possible taste; 4: best possible taste). An overall
comparison to usual cannabis was made (0: much worse
than usual cannabis; 4: much better that usual cannabis).
A global assessment was performed on the final day at
which subjects were asked to rank the products assessed in
order of preference (0: worse; 4: best). Subjects were not
asked about clinical parameters such as efficacy.
Eligible subjects were given a scheduled series of 4
appointments. Informed consent was signed at the first
appointment. The subjects were randomly assigned to test
one cannabis preparation per day over the four days. They
were asked to assess physical characteristics of the drug
prior to use. They were asked to prepare and use the can-
nabis in the manner to which they were accustomed.
Within five minutes of use they were asked to comment
on the harshness, hotness, burn rate and comparison with
usual cannabis. Subjects remained in the cannabis labora-
tory for one hour after use before being allowed to return
home by taxi. On the evening after each clinic visit the
subjects were contacted at home by the research nurse to
determine if they had additional comments or concerns
regarding the product they evaluated that day.
It was estimated that recruiting 8 subjects would allow a
basic and preliminary assessment of trends in perceptions
of differences between product characteristics. This
number of subjects was also feasible to recruit within the
time period of the study. The data were double entered
and validated in a dedicated and secure database. Data
were entered without identifiers to protect confidentiality.
Cannabis preparations were ranked according to user
preferences on each item. All items were rated equally. A
total rank score for each preparation was assigned. Ranks
according to individual physical and smoking characteris-
tics were examined. All statistical analyses were done
using SAS (SAS Institute, North Carolina). Means, fre-
quencies and a multiple analysis of variance (ANOVA) for
cross-over design (proc mixed) were calculated to assess
the comparison between products. Period effect was ana-
lyzed independently. Due to the small sample-size, no
adjustments were made for multiple comparisons.
The study was conducted at a dedicated cannabis research
laboratory at the Montreal General Hospital in the McGill
University Health Centre (MUHC). The study was
approved by the Research Ethics Committee of the McGill
University Health Centre.
Results
Eight subjects were recruited for the study. No subject
refused to participate, but one subject did not attend for
the final visit and was excluded from the final analysis.Harm Reduction Journal 2006, 3:32 http://www.harmreductionjournal.com/content/3/1/32
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Therefore the final report is based on seven subjects who
completed the study. Inclusion of the eighth subject in a
limited analysis did not alter the overall direction of the
results. The period effect could not be assessed in the main
model because one subject missed one visit; however no
overall differences were found on overall comparison of
the four time periods.
There were 5 males and 2 females, and the mean age was
47 years (range 40–54 y). Diagnoses were varied and
included peripheral neuropathic pain (4 subjects), multi-
ple sclerosis (2 subjects), and HIV/AIDS (1 subject).
The overall results based on the Likert scores for each char-
acteristic and the overall scores are shown in Table 1.
Product 1 (10.6% THC, 14.4% humidity, 10 mm grind
size) was the most well rated product, and significant dif-
ferences were noted between products overall (p = 0.03),
and for physical characteristics including general appear-
ance (p = 0.03) and colour (p = 0.03).
Of the 28 different assessments (7 subjects using 4 prod-
ucts), 18 were performed using joints and 10 using pipes.
Most assessments (93%) were done with subjects report-
ing using the same amount of cannabis as usual, and 16/
18 stated no problems in preparing their joints. Product 4
received a poor rating in terms of problems rolling it by 2
subjects.
Physical characteristics
Product 2 was treated as having the best smell with 6 sub-
jects rating it pleasant or very pleasant. Product 2 was also
rated as the best humidity with 6 subjects rating it accept-
able. In general appearance, product 1 was superior; 4
subjects rated product 3 as 'looks bad'. Products 1, 2 and
3 were rated similar in terms of ease of preparation,
although all 7 subjects rated products 1 and 2 as easy or
very easy to use. Products 1 and 2 were rated equally in
terms of colour. Product 1 was rated best in terms of par-
ticle size with 5 subjects rating particle size as good or
excellent.
Smoking characteristics
Product 3 was rated most 'cool' overall. Product 2 was
rated highest in terms of harshness with 6 subjects rating
it as moderate or smooth. Product 1 was rated as having
the best burn rate (1 subject stated it 'burned just right'),
while each of products 2, 3 and 4 were rated by one sub-
ject each as burning too fast. Product 2 was rated as having
the best overall taste.
Global assessments
Fourteen out of 28 (50%) subjects rated products 1, 3 and
4 as 'worse than their usual cannabis', 11 assessments
were the 'same as usual cannabis' (4 of which were for
product 2). Only 3 assessments were 'better than usual
cannabis' (products 1, 2 and 4). Globally, product 1
Table 1: Evaluation of four cannabis preparations by physical and smoking characteristics*
Characteristic Product p-value Contrasts
1234
Cannabis 
preparation
THC (g%) 10.6 10.6 6.6 9.6
Humidity (%) 14.4 12 11 11
Drying time 
(days)
2444
Grind size 
(mm)
10 5 5 10
Physical
Smell 2.71 3.00 2.57 2.43 0.21
Humidity 1.71 1.86 1.71 1.14 0.28
General 
appearance
2.71 2.29 1.43 1.86 0.03 1>3,4
Ease of 
preparation
3.29 3.14 3.29 2.86 0.55
Colour 2.71 2.71 2.00 2.43 0.03 1,2>3
Particle size 2.86 2.43 1.57 1.86 0.06
Smoking
Hotness 1.86 1.86 2.14 1.86 0.81
Harshness 2.14 2.14 1.43 1.71 0.53
Burn rate 2.57 2.29 1.86 2.00 0.55
Taste 2.00 2.14 1.29 2.00 0.41
TOTAL SCORE 24.57 23.86 19.29 20.14 0.03 1,2>3,4
*Characteristic scores based on 5-point Likert scales (0–4). Higher scores reflect better ratings for each characteristic. See text for details.Harm Reduction Journal 2006, 3:32 http://www.harmreductionjournal.com/content/3/1/32
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received the highest score in terms of all the product char-
acteristics measured (Table 2). In this overall analysis,
product 1 was superior to products 3 and 4, and product
2 was superior to product 3.
Of the products tested, over half (4/7) of those using
products 1 and 2 would use it on a regular basis, and over
half would not use products 3 (5/7) and 4 (5/6) on a reg-
ular basis. In terms of overall satisfaction, 3 subjects rated
product 1 as good or excellent and 2 subjects rated the
other products as good or excellent. Five subjects rated
product 3 as poor, and one rated product 2 as very poor.
Ambient humidity and temperature
The drug samples were prepared the day before the visit
for the first 5 patients, resulting in the drug being in the
new container for 16 to 20 hours. For the last 3 patients,
the drug spent from 6 to 17 days in the new container.
Temperature and humidity measurements were taken in
the pharmacy on 14 days over the 28 day period. Over this
period, the mean room temperature was 22.4°C (SD
0.23), and the mean ambient humidity was 46% (SD 4.4).
Discussion
To our knowledge, this is the first ever evaluation of med-
ical cannabis products for physical and smoking charac-
teristics by authorized patients. We have shown that
subjects may appreciate differences between cannabis
preparations on the basis of physical characteristics of the
herbal material, specifically general appearance and col-
our. We did not show differences in individual smoking
characteristics, but overall impressions confirmed that
subjects favoured higher THC content, higher humidity
and larger grind size.
The results of this study must be interpreted with consid-
erable caution as there are many limitations to the data
obtained. The small sample size reduces the power of the
study to reach definitive conclusions about patient prefer-
ence. The detected differences between products could
have arisen by chance, or may have been influenced by
other factors such as the use of different modes of admin-
istration (pipes and joints). Further study should limit the
modes of administration to reduce confounding by these
factors.
The effect of room air on the humidity levels of the prod-
uct is a factor which may affect the validity of the final
results. The average ambient humidity at the time of prod-
uct preparation was well above that of the original prod-
uct specifications (46% versus 10–15%), and could have
raised the humidity of the product during the storage
period prior to use. This would have the effect of reducing
or eliminating the potential differences between products
on humidity-based assessments. This may partially
explain why differences in physical characteristics such as
colour, particle size and general appearance were detected
(Table 2), while the hotness, harshness and burn rate
appeared to be rated similarly between products.
Subjects' evaluations of smoking characteristics of the
samples immediately after use may have been influenced
by the psychoactive effects of cannabis. This study
recruited experienced medicinal cannabis users who
would likely evaluate any cannabis product under similar
conditions ('try it and see') so we feel our approach is
pragmatic and relevant.
The subjects and investigators were initially blind to the
characteristics of the allocated products, but the ability of
the subjects to differentiate the products suggests that the
blinded condition was compromised. The investigators
(study nurse or physician) did not evaluate their own abil-
ity to differentiate the products
In spite of these potential limitations, this randomized
double-blind study has found that two of these products
(products 1 and 2) could be appreciated differently from
the other two, in terms of their physical and smoking
characteristics. Product 3, which was a 10% THC blend
(expiry date June 2004) which had been originally
shipped by Health Canada to authorized patients was
rated poorly by the subjects in this study, suggesting that
the product could be improved by changing physical char-
acteristics such as blending, particle size and humidity.
These changes may result in improved patient satisfaction
with the product, which may in turn increase the number
of patients willing to use the Health Canada product and
improve compliance in long term studies using the prod-
uct. The study results support a decision by Health Can-
ada, made prior to the study in May 2004, to distribute a
product made only of flowering head material, taking into
account preliminary reports from authorized users, with
larger grind size, higher humidity and higher THC con-
tent. A review of Health Canada statistics [10] suggests
that use of the Health Canada product increased since the
new product was shipped in the summer of 2004 (Figure
1). An initial delay in uptake may have been due to media
reports from disgruntled users about the poor quality of
the product [11].
This study should ideally be repeated with larger numbers
to validate differences between products. The reliability of
the subjects' reports may also be validated by repeating
the test with the same subjects and products to see if there
is reliability between their assessments over time. Future
studies of the effect of humidity could be done with sub-
jects removing cannabis directly from an unopened origi-
nal package prior to use rather than going through
pharmacy dispensing. Methods of rehumidification ofHarm Reduction Journal 2006, 3:32 http://www.harmreductionjournal.com/content/3/1/32
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herbal material should be explored. Finally, this study
design may also be used to detect differences between can-
nabis products with different cannabinoid profiles or phe-
notypic characteristics.
Conclusion
We have shown that medical cannabis users may discrim-
inate between cannabis preparations based on physical
characteristics such as humidity, grind size, and smoking
characteristics. The supply of a standardized herbal canna-
bis product within a legal medical access program needs
to be guided by user's feedback to ensure compliance. Fur-
ther work is required on other characteristics such as the
profile of cannabinoids and other constituents.
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